Bradley smiles at the camera

As a charity dedicated to fighting neuroblastoma, we are devastated to learn of Bradley’s passing. Like many, we have followed his journey, admiring his courage and spirit but deeply saddened by his plight at the hands of this disease.

Neuroblastoma has taken another innocent child, starkly reinforcing the fact that we need more help to work faster to #defeatneuroblastoma, eradicating the devastation the disease causes.

Neuroblastoma targets babies and toddlers and it struck Bradley when he was just 18 months old. He was diagnosed with the most aggressive form of the disease, stage 4 high-risk, which has just a 30-40% chance of survival long-term. Bradley’s diagnosis is typical for half of all neuroblastoma cases and requires the most intensive medical intervention of any type of cancer.

Following multi-modal therapy and major surgery to remove his tumours in 2014, Bradley got the all clear from neuroblastoma. Then just 18 months later, he relapsed.

Relapse is common for children with the same form of neuroblastoma as Bradley, the thought of which terrifies families. There is no standard treatment path for children with relapsed neuroblastoma and the survival rate is less than 10%. Upon relapse, families like Bradley’s are thrown in to the complex realm of clinical trials. Many will start fundraising with the aim of accessing experimental treatment urgently for their child that’s not yet available in the UK and which costs hundreds of thousands of pounds.

Bradley’s family held such hope and left no stone unturned in their quest for a cure for him. Seeking out information and answers, they attended our Neuroblastoma Parent Education Conference in December 2016 to hear from neuroblastoma experts about national and international clinical trial options for Bradley.

In a cruel twist of fate, that same month doctors declared Bradley’s condition terminal.

Our parent-led charity is passionate about working to ensure that no child dies from neuroblastoma and no child suffers as a result of its treatment, and we urge you to join our fight. Preventing the suffering and dying of children like Bradley is possible, but not without significant investment in the most promising research. Only this will lead to more effective and less toxic treatments for children, and reduce their suffering.

We thank and admire Bradley and his family for everything they have done to raise awareness of the plight of every child and family facing this disease. Our hearts are with them at this desperately sad time.